NCT05399030View on ClinicalTrials.gov

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 14, 2021

Primary Completion Date

January 30, 2022

Study Completion Date

February 18, 2022

Conditions

Healthy Subjects

Interventions

DRUG

ICP-332

ICP-332 will be administered as tablet

OTHER

Placebo

Matching placebo will be administered as tablet

Trial Locations (1)

250013

Jinan Central Hospital, Jinan

All Listed Sponsors

lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT05399030 - A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects | Biotech Hunter | Biotech Hunter